Article

Functional multi-omics reveals genetic and pharmacologic regulation of surface CD38 in multiple myeloma

2021-08-06

Abstract excerpt

CD38 is a surface ectoenzyme expressed at high levels on myeloma plasma cells and is the target for the monoclonal antibodies (mAbs) daratumumab and isatuximab. Pre-treatment CD38 density on tumor cells is an important determinant of mAb efficacy. Several small molecules have been found to increase tumor surface CD38, with the goal of boosting mAb efficacy in a co-treatment strategy. Numerous other CD38-targeting...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: f0ab5d03-d419-59d4-acd9-ca7b60f080e9
DOI: 10.1101/2021.08.04.455165

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Functional multi-omics reveals genetic and pharmacologic regulation of surface CD38 in multiple myelomaDOI 10.1101/2021.08.04.455165Read

Utilizing Genomics to Identify Novel Immunotherapeutic Targets in Multiple Myeloma High-Risk SubgroupsSemantic proximity Read

DNA methyltransferase inhibitors upregulate CD38 protein expression and enhance daratumumab efficacy in multiple myelomaSemantic proximity Read

Ablation of CD38 in multiple myeloma cells leads to an aggressive phenotype in a mouse xenograft model.Semantic proximity Read

Genomic and immune determinants of resistance to anti-CD38 monoclonal antibody-based therapy in relapsed refractory multiple myelomaSemantic proximity Read

Upregulation of CD38 expression on multiple myeloma cells by novel HDAC6 inhibitors is a class effect and augments the efficacy of daratumumabSemantic proximity Read

Comprehensive Characterization of the Multiple Myeloma Immune Microenvironment Using Integrated scRNA-seq, CyTOF, and CITE-seq AnalysisSemantic proximity Read

Genomic and immune determinants of resistance to daratumumab-based therapy in relapsed refractory multiple myelomaSemantic proximity Read

Unveiling the cellular landscape: insights from single-cell RNA sequencing in multiple myelomaSemantic proximity Read

CD38 biallelic loss is a recurrent mechanism of resistance to anti-CD38 antibodies in multiple myelomaSemantic proximity Read

IMiDs prime myeloma cells for daratumumab-mediated cytotoxicity through loss of Ikaros and AiolosSemantic proximity Read

Integrated Phosphoproteomics and Transcriptional Classifiers Reveal Hidden RAS Signaling Dynamics in Multiple MyelomaSemantic proximity Read

Target antigen and plasma cell phenotype are critical factors for sensitivity to response-adapted daratumumab therapy.Semantic proximity Read